Generic Mavyret Availability

Last updated on Apr 10, 2025.

Mavyret is a brand name of glecaprevir/pibrentasvir, approved by the FDA in the following formulation(s):

MAVYRET (glecaprevir; pibrentasvir - pellets;oral)

• Manufacturer: ABBVIE
  Approval date: June 10, 2021
  Strength(s): 50MG;20MG/PACKET ^[RLD]

MAVYRET (glecaprevir; pibrentasvir - tablet;oral)

• Manufacturer: ABBVIE
  Approval date: August 3, 2017
  Strength(s): 100MG;40MG ^[RLD]

Is there a generic version of Mavyret available?

No. There is currently no therapeutically equivalent version of Mavyret available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mavyret. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Anti-viral compounds
  Patent 10,028,937
  Issued: July 24, 2018
  Inventor(s): Bellizzi Mary E. & Betebenner David A. & Califano Jean-Christophe C. & Carroll William A. & Caspi Daniel D. & DeGoey David A. & Donner Pamela L. & Flentge Charles A. & Gao Yi & Hutchins Charles W. & Hutchinson Douglas K. & Jinkerson Tammie K. & Kati Warren M. & Keddy Ryan G. & Krueg
  Assignee(s): AbbVie Inc.
  

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  Patent expiration dates:

  • June 10, 2030
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG
  • June 10, 2030
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
  • June 10, 2030
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG
• Anti-viral compounds
  Patent 10028937*PE
  Issued: July 24, 2018
  Inventor(s): Bellizzi Mary E. & Betebenner David A. & Califano Jean-Christophe C. & Carroll William A. & Caspi Daniel D. & DeGoey David A. & Donner Pamela L. & Flentge Charles A. & Gao Yi & Hutchins Charles W. & Hutchinson Douglas K. & Jinkerson Tammie K. & Kati Warren M. & Keddy Ryan G. & Krueg
  Assignee(s): AbbVie Inc.
  

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  Patent expiration dates:

  • December 10, 2030
    
• Anti-viral compounds
  Patent 10,039,754
  Issued: August 7, 2018
  Inventor(s): Bellizzi Mary E. & Betebenner David A. & Califano Jean-Christophe C. & Carroll William A. & Caspi Daniel D. & DeGoey David A. & Donner Pamela L. & Flentge Charles A. & Gao Yi & Hutchins Charles W. & Hutchinson Douglas K. & Jinkerson Tammie K. & Kati Warren M. & Keddy Ryan G. & Krueg
  Assignee(s): AbbVie Inc.
  

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  Patent expiration dates:

  • June 10, 2030
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG
  • June 10, 2030
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
  • June 10, 2030
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG
• Anti-viral compounds
  Patent 10039754*PE
  Issued: August 7, 2018
  Inventor(s): Bellizzi Mary E. & Betebenner David A. & Califano Jean-Christophe C. & Carroll William A. & Caspi Daniel D. & DeGoey David A. & Donner Pamela L. & Flentge Charles A. & Gao Yi & Hutchins Charles W. & Hutchinson Douglas K. & Jinkerson Tammie K. & Kati Warren M. & Keddy Ryan G. & Krueg
  Assignee(s): AbbVie Inc.
  

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  Patent expiration dates:

  • December 10, 2030
    
• Method for treating HCV
  Patent 10,286,029
  Issued: May 14, 2019
  Inventor(s): Awni Walid M. & Bernstein Barry M. & Campbell Andrew L. & Dutta Sandeep & Lin Chih-Wei & Liu Wei & Menon Rajeev M. & Podsadecki Thomas J. & Wang Tianli & Mensing Sven
  Assignee(s): AbbVie Inc.
  

  The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG
  • March 14, 2034
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG
• Method for treating HCV
  Patent 10286029*PE
  Issued: May 14, 2019
  Inventor(s): Awni Walid M. & Bernstein Barry M. & Campbell Andrew L. & Dutta Sandeep & Lin Chih-Wei & Liu Wei & Menon Rajeev M. & Podsadecki Thomas J. & Wang Tianli & Mensing Sven
  Assignee(s): AbbVie Inc.
  

  The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

  Patent expiration dates:

  • September 14, 2034
    
• Solid pharmaceutical compositions for treating HCV
  Patent 11,246,866
  Issued: February 15, 2022
  Inventor(s): Sever; Nancy E. et al.
  Assignee(s): AbbVie Inc. (North Chicago, IL)
  

  The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

  Patent expiration dates:

  • June 24, 2036
    
    ✓ 
    Drug product
• Solid pharmaceutical compositions for treating HCV
  Patent 11246866*PE
  Issued: February 15, 2022
  Inventor(s): Sever; Nancy E. et al.
  Assignee(s): AbbVie Inc. (North Chicago, IL)
  

  The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

  Patent expiration dates:

  • December 24, 2036
    
• Methods for treating HCV
  Patent 11,484,534
  Issued: November 1, 2022
  Inventor(s): Awni; Walid M. et al.
  Assignee(s): AbbVie Inc. (North Chicago, IL)
  

  The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG
• Methods for treating HCV
  Patent 11484534*PE
  Issued: November 1, 2022
  Inventor(s): Awni; Walid M. et al.
  Assignee(s): AbbVie Inc. (North Chicago, IL)
  

  The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

  Patent expiration dates:

  • September 14, 2034
    
• Macrocyclic proline derived HCV serine protease inhibitors
  Patent 8,648,037
  Issued: February 11, 2014
  Inventor(s): Or Yat Sun & Ma Jun & Wang Guoqiang & Long Jiang & Wang Bin
  Assignee(s): Enanta Pharmaceuticals, Inc.
  

  The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof:

  Patent expiration dates:

  • January 19, 2032
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • January 19, 2032
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • January 19, 2032
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Macrocyclic proline derived HCV serine protease inhibitors
  Patent 8648037*PED
  Issued: February 11, 2014
  Inventor(s): Or Yat Sun & Ma Jun & Wang Guoqiang & Long Jiang & Wang Bin
  Assignee(s): Enanta Pharmaceuticals, Inc.
  

  The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof:

  Patent expiration dates:

  • July 19, 2032
    
    ✓ 
    Pediatric exclusivity
• Anti-viral compounds
  Patent 8,937,150
  Issued: January 20, 2015
  Inventor(s): DeGoey David A. & Kati Warren M. & Hutchins Charles W. & Donner Pamela L. & Krueger Allan C. & Randolph John T. & Motter Christopher E. & Nelson Lissa T. & Patel Sachin V. & Matulenko Mark A. & Keddy Ryan G. & Jinkerson Tammie K. & Gao Yi & Liu Dachun & Pratt John K. & Rockway Todd W.
  Assignee(s): AbbVie Inc.
  

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  Patent expiration dates:

  • May 18, 2032
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Anti-viral compounds
  Patent 8937150*PED
  Issued: January 20, 2015
  Inventor(s): DeGoey David A. & Kati Warren M. & Hutchins Charles W. & Donner Pamela L. & Krueger Allan C. & Randolph John T. & Motter Christopher E. & Nelson Lissa T. & Patel Sachin V. & Matulenko Mark A. & Keddy Ryan G. & Jinkerson Tammie K. & Gao Yi & Liu Dachun & Pratt John K. & Rockway Todd W.
  Assignee(s): AbbVie Inc.
  

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  Patent expiration dates:

  • November 18, 2032
    
    ✓ 
    Pediatric exclusivity
• Crystal forms
  Patent 9,321,807
  Issued: April 26, 2016
  Inventor(s): Chen Shuang & Gates Bradley D. & Sheikh Ahmad Y.
  Assignee(s): AbbVie Inc.
  

  The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of FIGS. -

  Patent expiration dates:

  • June 5, 2035
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • June 5, 2035
    
    ✓ 
    Drug substance
• Crystal forms
  Patent 9321807*PED
  Issued: April 26, 2016
  Inventor(s): Chen Shuang & Gates Bradley D. & Sheikh Ahmad Y.
  Assignee(s): AbbVie Inc.
  

  The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of FIGS. -

  Patent expiration dates:

  • December 5, 2035
    
    ✓ 
    Pediatric exclusivity
• Anti-viral compounds
  Patent 9,586,978
  Issued: March 7, 2017
  Inventor(s): Bellizzi Mary E. & Betebenner David A. & Califano Jean C. & Carroll William A. & Caspi Daniel D. & DeGoey David A. & Donner Pamela L. & Flentge Charles A. & Gao Yi & Hutchins Charles W. & Hutchinson Douglas K. & Jinkerson Tammie K. & Kati Warren M. & Keddy Ryan G. & Krueger Allan C.
  Assignee(s): AbbVie Inc.
  

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  Patent expiration dates:

  • November 6, 2030
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG
  • November 6, 2030
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
  • November 6, 2030
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG
• Anti-viral compounds
  Patent 9586978*PED
  Issued: March 7, 2017
  Inventor(s): Bellizzi Mary E. & Betebenner David A. & Califano Jean C. & Carroll William A. & Caspi Daniel D. & DeGoey David A. & Donner Pamela L. & Flentge Charles A. & Gao Yi & Hutchins Charles W. & Hutchinson Douglas K. & Jinkerson Tammie K. & Kati Warren M. & Keddy Ryan G. & Krueger Allan C.
  Assignee(s): AbbVie Inc.
  

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  Patent expiration dates:

  • May 6, 2031
    
    ✓ 
    Pediatric exclusivity
• Crystal forms
  Patent RE48923
  Issued: February 8, 2022
  Inventor(s): Califano Jean-Christophe & Fickes Michael G. & Nordstroem Lars Fredrik
  Assignee(s): AbbVie Inc.
  

  The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in one of FIGS. -

  Patent expiration dates:

  • May 8, 2035
    
    ✓ 
    Drug substance
• Crystal forms
  Patent RE48923*PED
  Issued: February 8, 2022
  Inventor(s): Califano Jean-Christophe & Fickes Michael G. & Nordstroem Lars Fredrik
  Assignee(s): AbbVie Inc.
  

  The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in one of FIGS. -

  Patent expiration dates:

  • November 8, 2035
    
    ✓ 
    Pediatric exclusivity

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • April 30, 2026 - TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1,2,3,4,5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A)
  • April 30, 2026 - TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH
  • October 30, 2026 - PEDIATRIC EXCLUSIVITY
  • June 10, 2028 - FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A); AND TREATME
  • December 10, 2028 - PEDIATRIC EXCLUSIVITY

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer